{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:32:27Z","timestamp":1760059947002,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The COVID-19 pandemic disrupted cancer care, prompting adaptations to reduce patient exposure while preserving treatment efficacy. This retrospective observational study compared a weekly cisplatin and 5-fluorouracil (5-FU) regimen to the standard monthly regimen for neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Materials and Methods: This single-center retrospective study included 91 patients, divided into two cohorts: weekly chemotherapy (n = 30) and standard chemotherapy (n = 61). Treatment assignment was based on hospital policy changes during the pandemic, with weekly outpatient chemotherapy implemented after November 2022 to conserve inpatient resources. All patients received radiotherapy at 50 Gy in 25 fractions. The weekly regimen consisted of cisplatin 20 mg\/m2 and 5-FU 800 mg\/m2, administered over 1\u20132 h weekly, while the standard regimen administered the same doses over four consecutive days on weeks 1 and 5. Primary endpoints were pathologic complete response (pCR), progression-free survival (PFS), and overall survival (OS). Results: The response rates were similar between groups (weekly: 86.7% vs. standard: 90.2%; p = 0.724). The weekly regimen group showed a higher pCR (40.0% vs. 26.2%; p = 0.181) and significantly lower recurrence (26.7% vs. 52.5%; p = 0.020). Mortality was also reduced in the weekly group (6.7% vs. 34.4%; p = 0.004), though the follow-up duration was shorter (10.6 vs. 22.8 months; p &lt; 0.001). Conclusions: In this retrospective observational study, weekly cisplatin and 5-FU demonstrated comparable efficacy to the standard regimen, with potential advantages in reducing recurrence and mortality. This modified approach may be a viable alternative for maintaining oncologic outcomes while minimizing the burden on healthcare systems during pandemic conditions, although prospective validation is needed.<\/jats:p>","DOI":"10.3390\/medicina61081326","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:49:17Z","timestamp":1753267757000},"page":"1326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Weekly Cisplatin and 5-Fluorouracil in Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Pandemic-Era Evaluation"],"prefix":"10.3390","volume":"61","author":[{"given":"Yi-Ting","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yen","family":"Chuang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung 407219, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-6448","authenticated-orcid":false,"given":"Chien-Chih","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407219, Taiwan"},{"name":"Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 406053, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","article-title":"Phase III Trial of Trimodality Therapy with Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared with Surgery Alone for Esophageal Cancer: CALGB 9781","volume":"26","author":"Tepper","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s43018-024-00880-4","article-title":"The Global Impact of the COVID-19 Pandemic on Delays and Disruptions in Cancer Care Services: A Systematic Review and Meta-Analysis","volume":"6","author":"Shah","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jss.2022.12.018","article-title":"The COVID-19 Era Is Associated With Delays in Esophageal Cancer Diagnosis and Treatment","volume":"285","author":"Khan","year":"2023","journal-title":"J. Surg. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1017\/ice.2020.237","article-title":"Current Knowledge of COVID-19 and Infection Prevention and Control Strategies in Healthcare Settings: A Global Analysis","volume":"41","author":"Islam","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_8","first-page":"50","article-title":"A Multi-Centre Survey Reveals Variations in the Standard Treatments and Treatment Modifications for Head and Neck Cancer Patients During COVID-19 Pandemic","volume":"30","author":"Vasiliadou","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdi207","article-title":"High Pathological Response Rate in Locally Advanced Esophageal Cancer after Neoadjuvant Combined Modality Therapy: Dose Finding of a Weekly Chemotherapy Schedule with Protracted Venous Infusion of 5-Fluorouracil and Dose Escalation of Cisplatin, Docetaxel and Concurrent Radiotherapy","volume":"16","author":"Pasini","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/annonc\/mdl339","article-title":"Concurrent Chemoradiotherapy with Twice Weekly Paclitaxel and Cisplatin Followed by Esophagectomy for Locally Advanced Esophageal Cancer","volume":"18","author":"Lin","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cncr.27822","article-title":"Neoadjuvant Therapy with Weekly Docetaxel and Cisplatin, 5-Fluorouracil Continuous Infusion, and Concurrent Radiotherapy in Patients with Locally Advanced Esophageal Cancer Produced a High Percentage of Long-Lasting Pathological Complete Response: A Phase 2 Study","volume":"119","author":"Pasini","year":"2013","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"308-e625","DOI":"10.1634\/theoncologist.2019-0931","article-title":"Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study","volume":"25","author":"Chen","year":"2020","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2006.03.010","article-title":"A Phase II Study of Concomitant Boost Radiation plus Concurrent Weekly Cisplatin for Locally Advanced Unresectable Head and Neck Carcinomas","volume":"79","author":"Medina","year":"2006","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hed.20111","article-title":"Hyperfractionated Accelerated Radiotherapy in Combination with Weekly Cisplatin for Locally Advanced Head and Neck Cancer","volume":"27","author":"Beckmann","year":"2005","journal-title":"Head Neck"},{"key":"ref_15","first-page":"XC07","article-title":"A Comparative Study on Weekly Versus Three Weekly Cisplatinum Based Chemoradiation in Locally Advanced Head and Neck Cancers","volume":"11","author":"Sahoo","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_16","first-page":"6","article-title":"Weekly versus Three-Weekly Cisplatin-Based Concurrent Chemoradiotherapy as Definitive Treatment in Head and Neck Cancer\u2014Where Do We Stand?","volume":"1","author":"Rawat","year":"2016","journal-title":"Gulf J. Oncolog."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.7314\/APJCP.2015.16.16.7309","article-title":"Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: A Single Institution Study","volume":"16","author":"Ghosh","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.oraloncology.2011.10.005","article-title":"Weekly and 3-Weekly Cisplatin Concurrent with Intensity-Modulated Radiotherapy in Locally Advanced Head and Neck Squamous Cell Cancer","volume":"48","author":"Espeli","year":"2012","journal-title":"Oral Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/07357907.2023.2283452","article-title":"Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin","volume":"41","author":"Veldman","year":"2023","journal-title":"Cancer Investig."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:27Z","timestamp":1760033667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["medicina61081326"],"URL":"https:\/\/doi.org\/10.3390\/medicina61081326","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}